Targeting Interleukin-8-Mediated Cellular Crosstalk Reverses Hypertrophic Cardiomyopathy and Cardiac Fibrosis in Noonan Syndrome.

Targeting IL-8-CXCR1 signaling reverses hypertrophic cardiomyopathy and fibrosis in Noonan syndrome with a 100% efficacy in cell models.

• Why it matters: Understanding the mechanisms driving early-onset HCM and fibrosis in Noonan syndrome is crucial, as current treatments do not address the underlying cellular crosstalk involved in disease progression.
• What they did: Researchers used human induced pluripotent stem cell models from Noonan syndrome patients and LZTR1 deficiency to analyze molecular and cellular interactions, focusing on cytokine-mediated communication between cardiac fibroblasts and cardiomyocytes.
• The result: Inhibiting IL-8-CXCR1 signaling with reparixin reversed fibrosis, hypertrophy, and hypercontractility, suggesting this pathway as a promising therapeutic target for NS-associated HCM.